"If you look at men who had sexual dysfunction at the beginning of the study, compared to men that had good sexual function at the beginning of a study, both groups of men have equal response to improvement in their lower urinary tract symptoms,” says Kevin T. McVary, MD, FACS.
In this video, Kevin McVary, MD, FACS, discusses the background and findings of the study, “Preservation of sexual function 5-years after water vapor thermal therapy for benign prostatic hyperplasia,” presented recently at the 2021 American Urological Association Annual Meeting. McVary is a professor of urology and director of the Center for Male Health at Loyola University Medical Center, Maywood, Illinois.
Lenvatinib plus pembrolizumab delays all organ tumor progression in advanced RCC
June 7th 2024“Overall, our results continue to support the use of lenvatinib and pembrolizumab as a current standard treatment option in the first-line treatment of [patients with] kidney cancer," says Viktor Grünwald, MD, PhD.